Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel with Cetuximab or Bortezomib in Advanced NSCLC
NCT00118183Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2005
- Primary completion
- Apr 2007
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140, bortezomib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Jul 2005; status: completed.
02
Drugs
KL-140bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00118183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118183.